Praxis Precision Medicines (PRAX)
US Market

Praxis Precision Medicines (PRAX) Stock Price & Analysis


PRAX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.79 - $9.01
Previous Close$1
Average Volume (3M)1.64M
Market Cap
Enterprise Value-$20.46M
Total Cash (Recent Filing)$85.82M
Total Debt (Recent Filing)$3.26M
Price to Earnings (P/E)-0.3
Nov 01, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.85
Shares Outstanding62,101,292
10 Day Avg. Volume591,385
30 Day Avg. Volume1,642,794
Standard Deviation0.34
Financial Highlights & Ratios
Price to Book (P/B)1.21
Price to Sales (P/S)90.92
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-29.96
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.11
Price Target Upside517.00% Upside
Rating ConsensusHold
Number of Analyst Covering4




What was Praxis Precision Medicines’s price range in the past 12 months?
Praxis Precision Medicines lowest stock price was $0.79 and its highest was $9.01 in the past 12 months.
    What is Praxis Precision Medicines’s market cap?
    Currently, no data Available
    When is Praxis Precision Medicines’s upcoming earnings report date?
    Praxis Precision Medicines’s upcoming earnings report date is Nov 01, 2023 which is in 157 days.
      How were Praxis Precision Medicines’s earnings last quarter?
      Praxis Precision Medicines released its earnings results on May 11, 2023. The company reported -$0.71 earnings per share for the quarter, beating the consensus estimate of -$0.785 by $0.075.
        Is Praxis Precision Medicines overvalued?
        According to Wall Street analysts Praxis Precision Medicines’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Praxis Precision Medicines pay dividends?
          Praxis Precision Medicines does not currently pay dividends.
          What is Praxis Precision Medicines’s EPS estimate?
          Praxis Precision Medicines’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Praxis Precision Medicines have?
          Praxis Precision Medicines has 62,101,290 shares outstanding.
            What happened to Praxis Precision Medicines’s price movement after its last earnings report?
            Praxis Precision Medicines reported an EPS of -$0.71 in its last earnings report, beating expectations of -$0.785. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Praxis Precision Medicines?
              Among the largest hedge funds holding Praxis Precision Medicines’s share is Baker Bros Advisors LP. It holds Praxis Precision Medicines’s shares valued at 2M.


                Praxis Precision Medicines Stock Smart Score

                The Praxis Precision Medicines stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Praxis Precision Medicines

                Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in developing therapies for patients and families affected by complex and debilitating brain disorders. The firm's pipeline covers PRAX-114, PRAX-944, PRAX-562, and PRAX-222 among others.


                Top 5 ETFs holding PRAX

                Currently, no data available
                Please return soon. This page is being updated.
                Up to five ETFs with an Outperform Smart Score that hold PRAX. The ETFs are listed according to market value of PRAX within the ETF


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Nuvectis Pharma
                ImmunoCellular Therapeutics
                Capricor Therapeutics
                Annovis Bio

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis